Gregory "Greg" Charles Simon (born 1951)

Nov 20019

Wikipedia 🌐 Greg Simon

Saved Wikipedia (July 22, 2023) for "Greg Simon"

Saved PDF : [HK00B8][GDrive]  

Greg Simon is an American political aide who supported Vice Presidents Joe Biden and Al Gore. His private sector work is concentrated in the pharmaceutical, biotechnology, and telecommunications sectors. Simon is credited with advancing key federal health care and telecommunications policies.[1]

Early life and education

Simon was a rock 'n roll drummer until he was thirty.[2] He received his J.D. degree from the University of Washington School of Law in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas.[1]

Career

Simon was an aide to Vice President Al Gore, eventually working as his Chief Domestic Policy Advisor (‘93-’97) where he shepherded the 1996 Telecommunications Reform Act, crafted regulations for the biotech industry, and represented VP Gore on the National Economic Council.

Simon left the White House to found lobbying firm Simon Strategies. With his firm Simon lobbied for energy companies Enron and Southern Company, and telecom companies such as Sony, Netscape, Motorola, Global Crossing, AOL, and Cisco.[3][2][4] [5]Simon also lobbied for domain registrar Network Solutions.[6]While maintaining his lobbying practice, Simon was a bundler and top advisor for Gore’s 2000 presidential campaign.[2][7]

Simon served as Executive Director for both the Biden Cancer Initiative (‘17-’19) and the White House Cancer Moonshot Task Force (2016).[citation needed] He also served on the Health and Human Services review team for the Obama-Biden transition in 2008.[8]

After working on the Obama-Biden transition team, Simon joined Pfizer as a Senior Vice President in charge of worldwide policy and patient engagement (2009-12).[1]

References

"Greg Simon" -  The Forum at Harvard T. H. Chan School of Public Health. Archived from the original on 2020-04-24. Retrieved 2020-05-21. 

Saved as PDF   [HX003H][GDrive]  

Saved as PDF   [HX003I][GDrive

Greg Simon was a panelist for The Forum’s discussion on Rare Cancers.

Mr. Simon serves as President of the Biden Cancer Initiative at the Biden Foundation. Previously, he was the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. As Executive Director, Greg assembled and led a team of eight professionals to support the work of the Vice President in developing and promoting the goals of the Cancer Moonshot in numerous meetings and presentations and to coordinate the work of the Task Force comprised of twenty cabinet and sub-cabinet offices.

Over the past ten months Greg and his team worked across the Task Force, academia and the private sector to create over seventy innovative collaborations. On October 17th, 2016, Greg joined the Vice President to present the Cancer Moonshot reports to President Obama in an Oval Office briefing. On December 7, 2016, the passage of the 21st Century Cures Act provided $1.8 billion for the Cancer Moonshot over the next seven years.

In his career, Greg has held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, was a senior strategy consultant to a variety of international technology CEO’s, co-founded and led FasterCures and the Melanoma Research Alliance, was the Senior Vice President at Pfizer for worldwide policy and public engagement and was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

Greg came to Washington, DC in 1985 as General Counsel and then Staff Director of the Investigations Subcommittee of the House of Representatives’ Science, Space and Technology Committee. During his years with the Science Committee, Greg organized a series of investigatory hearings on biotechnology policy and was involved in hearings and investigations related to NASA and the Challenger explosion, scientific misconduct, the use of human biological materials in research and the artificial heart program.

Mr. Simon served as Sen. Gore`s Legislative Director from 1991 to 1993 before joining him in the White House as his Chief Domestic Policy Advisor. He was the lead staffer for the Clinton-Gore Administration for development and passage of the Telecommunications Reform Act of 1996 as well as development of the National and Global Information Infrastructure. He represented the Vice President on the National Economic Council, helped negotiate the US-Russia agreement on the International Space Station and oversaw a number of key initiatives, including programs at the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Human Genome Project. He was also instrumental in crafting the regulatory framework that is now the foundation for the biotechnology industry.

Following his White House service Greg was CEO of Simon Strategies and provided strategic advice to CEO’s of major firms such as Sony, Cisco, Netscape, Motorola, Sega and AOL.

Starting in 2003, Mr. Simon worked with Mike Milken to co-found FasterCures/The Center for Accelerating Medical Solutions. FasterCures has become an organization valued and recognized for catalyzing systematic change in the process of discovery and development and of new therapies for deadly and debilitating diseases.

Under Greg’s leadership, FasterCures created the FasterCures Philanthropy Advisory Service, with funding from the Robert Wood Johnson Foundation and the Bill & Melinda Gates Foundation.  This initiative accelerates and increases the flow of philanthropic support to nonprofit medical research organizations by providing in-depth data on the methods, goals, and potential impacts of nonprofit medical research organizations engaged in specific disease areas. He also created The Research Acceleration and Innovation Network (TRAIN) to promote innovation in disease research and to support the activities of organizations engaged in cutting-edge research.

While at FasterCures Greg co-founded the Melanoma Research Alliance with Leon and Debra Black.

From 2009-1012 Simon was Senior Vice President for Worldwide Policy and Patient Engagement at Pfizer, Inc. He led a global team of professionals in:  1) worldwide government policy, 2) science policy, 3) economic policy and research, and 4) international policy. He advised the CEO on the company’s efforts in Healthcare Reform.  He also focused on engaging patients more productively in research and clinical trials and on helping Pfizer develop policies, practices, and medical solutions to improve health, happiness and productivity.

Prior to becoming Executive Director of the Cancer Moonshot, Greg was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Poliwogg’s first index, the Poliwogg Medical Breakthroughs Index, was the basis for the best performing health Exchange Traded Fund, “SBIO,” in 2015.

The journal Nature Medicine named Greg one of “Ten People to Watch” in health care policy, noting that he was among “a handful of influential people who quietly keep the wheels of biomedical science turning.” In 2010 he received the Genetic Alliance’s “Art of Advocacy” award. In May 2011 Greg was invited to be the second lecturer in the Constantin Spiegelfeld Lecture series of the Research Center for Molecular Medicine of the Austrian Academy of Sciences. He is the recipient of the Arab American Institute’s 2017 Najeem Halaby Public Service Award established by Queen Noor in memory of her father. He is a regular presenter at the Milken Institute Global Conference, the OECD, the Washington Campus (a nonprofit educational institution in Washington, D.C.) and at health conferences and academic institutions around the country.

He received his law degree from the University of Washington in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas.

EVIDENCE TIMELINE

1970 (Mar 13)

https://www.newspapers.com/image/9276070/?terms=%22greg%20Simon%22&match=1

Northwest_Arkansas_Times_Fri__Mar_13__1970_clip

1971 (Aug) - Fullbright scholarship award. Will get to study one year in Vienna.

https://www.newspapers.com/image/21550245/?terms=%22greg%20simon%22&match=1 

1974 (April 18) 

https://www.newspapers.com/image/412494650/?terms=%22greg%20simon%22&match=1

1985 - "Mr. Simon entered government service in 1985 as General Counsel and then Staff Director of the Investigations Subcommittee of the House of Representatives' Science, Space and Technology Committee"

Mr. Simon entered government service in 1985 as General Counsel and then Staff Director of the Investigations Subcommittee of the House of Representatives' Science, Space and Technology Committee, organizing some of the earliest investigatory hearings on biotechnology policy. Mr. Simon was Sen. Al Gore’s Legislative Director from 1991 to 1993, before joining his White House administration as Chief Domestic Policy Advisor. While at the White House, Mr. Simon helped develop the Telecommunications Reform Act of 1996 as well as National and Global Information Infrastructure initiatives and was instrumental in crafting the foundational regulatory framework for the biotechnology industry. 

1993 (Jan 15) - NYTimes : "THE NEW PRESIDENCY: President-Elect; Clinton Selects a Mostly Youthful Group of White House Aides"

By Richard L. Berke  /  Jan. 15, 1993  / Full article saved as PDF : [HN02DF][GDrive]  

[...]

Others in the White House inner circle will be Bruce Lindsay, a longtime friend of Mr. Clinton, who will be in charge of personnel; David Watkins, the campaign's director of operations, will head the office of Administration and Management; Christine Varney, the campaign's counsel, will be Cabinet secretary; John Podesta, a Democratic political consultant, will be staff secretary, and Nancy Hernreich, a longtime executive assistant to Mr. Clinton, will be in charge of appointments and scheduling.

The head of legislative affairs will be Howard Paster, Washington director of a public relations firm, and the head of public liaison will be Alexis Herman, who was chief executive of the Democratic convention.

Margaret A. Williams, a former communications director for the Children's Defense Fund, will be Mrs. Clinton's chief of staff. Vice President-elect Al Gore's chief of staff will be Roy Neel, his longtime top Senate aide.

Other White House appointments announced today were:

Office of the Counsel: Vince Foster, deputy counsel; Ron Klain and Cheryl Mills, assistant counsels.

Office of the First Lady: Melanne Verveer, deputy chief of staff; Lisa Caputo, press secretary; Ann Stock, social secretary, and Patty Solis, scheduling director.

Domestic Policy Council: Bruce Reed and William Galston, deputy assistants, and Shirley Sagawa, special assistant.

National Economic Council: Gene Sperling and W. Bowman Cutter, deputy assistants.

National Security Council: Nancy Soderberg, staff director.

Senior Adviser for Policy Development: Ira Magaziner.

Office of Communications: Ricki Seidman, David Dreyer and Jeff Eller, deputy assistants; Bob Boorstin, Michael Waldman, David Kusnet, Anne Walker and Keith Boykin, special assistants.

Legislative Affairs: Susan Brophy, deputy director, and Steve Richetti, special assistant.

Scheduling and Advance: Marcia Hale, director, Isabelle Rodriguez Tapia, deputy director.

Public Liaison: Doris Matsui, deputy director; Mike Lux and Amy Zisook, special assistants.

Political Affairs: Joan Baggett, deputy director, and Elaine Weiss, special assistant.

Intergovernmental Affairs: Regina Montoya, director, and Jeff Watson, deputy director.

Office of Vice President: Thurgood Marshall Jr., legislative affairs coordinator; Greg Simon, domestic policy adviser; Marla Romash, communications director; Leon Fuerth, national security; Jack Quinn, counsel, and Katie McGinty, special assistant for environment.

1993 (Dec 21) - NYTimes : "Science Group Asks Delay on Gene-Altered Foods"

Article saved as a PDF : [HN02DG][GDrive]  

Image of saved article : : [HN02DH][GDrive

With the first two genetically engineered crops a few months away from American food stores, a scientific policy organization called on the Government yesterday to delay commercial approval until the United States better understands the potential risks the plants may pose to the environment.

In a study intended to provoke the Clinton Administration into reconsidering policies that were instituted in the Reagan and Bush years, the organization, the Union of Concerned Scientists, said that the new plant technologies were not being adequately controlled by the Government.

Responding to the study, Greg Simon, the Administration's top biotechnology policy coordinator, said most of the issues it raised had been debated extensively within the Government and among scientists.

"The Department of Agriculture has done a very good job with the review of genetically engineered plants and on the environmental assessments of those plants," said Mr. Simon, the chief domestic policy adviser for Vice President Al Gore.

Roger Salquist, the chief executive officer of Calgene Inc., a plant biotechnology company in Davis, Calif., said that since 1986, when the Government instituted new procedures for testing genetically engineered plants outdoors, not a single experiment had indicated that the crops were an environmental threat. "If there had been even the slightest problems, they would have appeared in one of those tests," said Mr. Salquist, whose company developed a new tomato that is awaiting approval by the Food and Drug Administration so it can be marketed.

An F.D.A. spokesman said yesterday that the agency was expected to complete its review some time in the next two weeks, and the new tomato could be in food stores in a few months. A variety of squash is also near final approval.

The study, "Perils Amidst the Promise," is part of a new project at the Union of Concerned Scientists to identify technologies and develop policies to help make modern agriculture less destructive of the environment. In a preface, the chairman of the group, Henry W. Kendall, said he hoped the report would provoke "serious public discussion of whether transgenic crops are likely to advance or retard progress towards a more sustainable agriculture."

In the study, Dr. Margaret G. Mellon, a molecular virologist, and Dr. Jane Rissler, a plant pathologist, indicated that they had doubts that biotechnology would be as safe as the Government and the industry have said. Both scientists recently moved to the Union of Concerned Scientists from the National Wildlife Federation, one of the nation's largest conservation groups, where they were well-known critics of biotechnology.

Among the many concerns that Dr. Mellon and Dr. Rissler raised about the safety of plant biotechnology were two basic issues: the unknown effects of using genetic material from plant viruses, and the possibility of creating plants that were so hearty they could become pests themselves.

They said scientists are inserting genes from plant viruses into crops as a way of enhancing immunity to plant diseases. Dr. Mellon and Dr. Rissler argue that not nearly enough research has been conducted to say whether the technique is entirely safe, especially when used on a commercial scale of thousands of acres of new crops. There is the potential, they said, for genetic engineering to lead to the formation of new plant viruses that threaten crops across an entire region.

"There are experiments you could do to determine whether risks are real or not," said Dr. Mellon. "We are not doing them. We are assuming the risks are nonexistent, and with a technology this new, that's not good enough."

Dr. Rod Townsend, a plant pathologist, and director of regulatory affairs at Pioneer Hi-Bred International, a crop breeding company in Des Moines, said that scientists had studied this issue and that field testing of crops with viral genes had not produced any problems.

Dr. Mellon's and Dr. Rissler's second main concern involved the potential creation of a sort of super plant that could outcompete its natural relatives and itself become a weed. The two scientists urged the Government to require more extensive testing to prevent such a possibility.

Since 1987, the Department of Agriculture has regulated the outdoor testing of genetically engineered crops. The department reports that in that time, almost 500 such crops have been field tested and none have resulted in environmental damage.

But Dr. Mellon said the field tests had been conducted under conditions too carefully prescribed to determine long-range environmental risks. For instance, if the Government was interested in knowing whether a genetically engineered crop might become a weed, it should require that some plants be placed at the edges of a field near real weeds.

1994 (Sep 30)

https://www.c-span.org/video/?60573-1/national-information-infrastructure 

SEPTEMBER 30, 1994

National Information Infrastructure

A communications executive and two policy advisors talked about technology improvements and regulatory approvals which will contribute to the development of the national information superhighway. They said ultimately, competition, not mergers, will create the superhighway. close 

During the past three years, however, the FDA's biotechnology policy has undergone a sea change. This was accomplished in several ways. First, it is no coincidence that FDA Commissioner David Kessler is the only senior political appointee from the Bush administration still in government. He has survived by being willing to craft any policy, make any decision, cut any corner, in order to satisfy his political masters. Second, the vice president's influence is pervasive. Instructions from the Clinton administration are relayed from Gore's senior adviser for domestic policy, Greg Simon, via FDA's political commissar, a former Gore Senate s*affer named Jerold Mande, and several other senior off*cials with close personal or family ties to the vice president. Directives from the White House pertain to regulatory policies, decisions on individual products, and personnel changes. Their effect has been to undermine the scientific paradigm that has governed FDA policy for 15 years.

[ ....  } 

FDA's recent actions are damaging enough, but they leave the door open to oth ers that would be positively nefarious. If t he White House has directed agencies' decisions for reasons of ideology, how far-fetched is the idea that it might do so for reasons of politics? Who would be surprised, say, by White House encouragement to delay approval of a product made by a company known for giving generously to Republican causes or to expedite a product made by a company friendly to the administration? To those who would say that such unethical and illegal actions are unthinkable, particularly in an administration that promised its leaders would be moral exemplars, read on.

Since A1 Gore became vice president, he and Greg Simon have been intolerant of any challenge to their view of science policy. They have gone to extremes that Hazel O'Leary could only dream of, in order to purge their enemies -- extremes reminiscent of the Nixon administration.

To control science and technology policy and to rid the civil service of dissent, Gore and Simon have interfered improperly in personnel matters. Thus, while working for the vice president, Simon threatened a high-ranking official at the Department of Energy with retaliation if she hired the former assistant director of the National Science Foundation, David Kingsbury. Simon and Kingsbury had clashed on biotechnology policy in earlier years; while a congressional staffer, Simon had hounded Kingsbury from government with unsubstantiated charges of conflict of interest. Also while working for the vice president, Simon improperly ordered FDA to remove a senior civil servant from his position. An FDA official admitted that this was retribution for the " transgression" of having implemented Reagan-Bush-era policies. Gore himself dismissed Will Happer, a senior scientist at the Department of Energy, because Happer refused to ignore scientific evidence that conflicted with the vice president's theories on ozone depletion and global warming. Similar incidents have occurred at the departments of State, Energy, and Interior, and at EPA, where civil servants have been moved to less visible positions or temporarily replaced during interactions with the White House for their own "protection."

One has to wonder how much of this the president knows. The vice president's policies and actions conflict, after all, with Clinton's repeated promises to give the country "leaner, but not meaner," government. It is possible, of course, that on that point, as on others, Clinton has changed his mind.

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.hoover.org/sites/default/files/uploads/documents/0817939326_49.pdf 

FEBRUARY 29, 1996

White House Daily Briefing

Mr. Mike McCurry and others briefed reporters on various issues, including a Cuban-American memorial ceremony for the victims of the recent aircraft downing, the extension of the Whitewater investigation and President Clinton’s meeting with television industry executives about a ratings system. close 

https://www.c-span.org/video/?70224-1/white-house-daily-briefing 

1998 (Sep 29) - NYTimes :  "The Business of Persuasion Thrives in Nation's Capital"

https://www.nytimes.com/1998/09/29/us/the-business-of-persuasion-thrives-in-nation-s-capital.html?searchResultPosition=31

1998-09-29-nytimes-the-business-of-persuasion-thrives-in-nation-s-capital.pdf

By Jill Abramson  /   Sept. 29, 1998 

  • ''I haven't thought about Monica Lewinsky all day,'' mused Wright Andrews, a Washington lobbyist.
  • He was too busy. While the rest of Washington was obsessing over the President's sex scandal, Mr. Andrews and dozens of other business lobbyists were working on bankruptcy legislation that passed the Senate on Wednesday. Kenneth W. Starr's $40 million investigation may have dominated the headlines and caused misery for President Clinton, but $40 million was also spent on lobbying by the banking, credit card and retailing industries on a variety of bills, including bank legislation that would make it much tougher to declare personal bankruptcy.
  • This year has also, separately, been a banner year for K Street, the power corridor of law and lobbying firms that rims the White House in downtown Washington.
  • It started with extensive lobbying earlier in the year by the cigarette industry to crush a comprehensive tobacco bill, followed by efforts to influence major banking and bankruptcy legislation. With more lobbying yet to come on appropriations, trade and tax measures, Mr. Andrews and many lobbyists interviewed in recent months predicted that more would be spent on influencing the Federal Government this year than in 1997, when a record $1.2 billion was reportedly spent.
  • This rapid growth in spending has brought with it the rise of a new lobbying elite. At a time when the Democratic Administration and the Republican-led Congress are often at loggerheads and when Washington's agenda, dominated by scandal, seems inert, K Street's portfolio has never been more robust. That portfolio includes multimillion-dollar lobbying campaigns on issues like product liability law, health care and computer privacy.
  • They are issues that do not necessarily receive a lot of media attention though they affect millions of people.
  • All last week, for example, while the klieg lights were shining on the House Judiciary Committee's debate about the Starr report, swarms of tax lobbyists were crisscrossing the hallways outside the House Ways and Means Committee, known as Gucci Gulch, in an effort to preserve an array of business tax breaks in the House's $80 billion tax-cut package.
  • The influence industry was already on a growth curve in the 1980's, but that growth has exploded in recent years with the advent of a divided Government.
  • A new cast of Republican Congressional committee and subcommittee chairmen as well as Washington's increasing impact on highly regulated industries like financial services, telecommunications and health care has meant that corporations and lobbying firms are reaching much deeper into the bureaucracy in order to wield influence.
  • When Kenneth J. Kies left his Congressional staff position last winter for a million-dollar job lobbying for PricewaterhouseCoopers, Congressional committee chairmen, senior Treasury Department and White House officials turned out for a lavish farewell in the House Ways and Means Committee room, a testament to his connectedness.
  • The eye-popping salary package commanded by Mr. Kies, a 46-year-old Republican tax lawyer who earned $132,000 as chief of staff of the Joint Committee on Taxation, was fresh evidence of a culture of money that in the 1990's has begun to transform Washington's image as a power city.
  • Another bureaucrat who was unknown outside Washington, Bruce Merlin Fried, a senior administrator for Medicare and Medicaid programs at the Department of Health and Human Services, was also courted like a superstar when he left the Government last January.
  • ''I felt like I was representing Michael Jordan,'' said Susan Schneider, a legal headhunter who helped Mr. Fried choose among plum jobs at law and lobbying firms.
  • ''The demand for knowledgeable people who can track what is going on on Capitol Hill and the Government and can figure out the pressure points that companies should be touching in Washington has greatly increased,'' said Richard Shapiro, executive director of the Congressional Management Foundation, a private organization that tries to educate Congress on running its business.
  • Almost anyone with significant political connections, including the spouses, family members and former aides of lawmakers, is highly marketable on K Street. Michelle Laxalt, for example, the daughter of Paul Laxalt, a former Republican Senator, is sought after as a lobbyist for her Senate connections.
  • Boutique firms that specialize in lobbying a single member or a single committee of Congress have also sprouted up and are flourishing. Ann M. Eppard, who for 22 years served as a top aide to Bud Shuster, the House Transportation Committee chairman, left her job in 1994 and hung out her shingle as a transportation lobbyist. Within months, she had lined up more than $1 million in retainers from an array of big transportation companies, including the FDX Corporation.
  • Some denizens of the capital say that K Street's explosion has fundamentally changed the city's atmosphere, with a new obsession with money eclipsing Washington's traditional obsession with power.
  • ''New York was money, Los Angeles was glamour and Washington was always power,'' said Victor Kamber, a lobbyist and a political consultant for 32 years whose firm billed $11 million last year. ''Now this town is as much about money as power.''

Dollars on Parade -  A World Awash With Big Money

  • Washington has long been one of the nation's wealthiest metropolitan areas, with a large population of Government workers and white-collar professionals. But its elite, led by a stratum of highly paid lawyers and lobbyists, has never been as brazen in advertising its money or political connections.
  • At the Capital Grille, an expensive restaurant that opened near the Capitol in 1994, lobbyists flaunt their clients and their expensive tastes with brass name plaques on private wine lockers.
  • So many wealthy Washingtonians are buying second homes along Maryland's once-quaint Eastern Shore that some areas are taking on the congested feel of New York's Hamptons on summer weekends. And a new glossy magazine, Capital Style, regularly profiles the lives of Washington's rich and famous.
  • Nothing seems to restrain this new culture. Not tighter revolving-door rules signed by President Clinton that lengthened the time that some lobbyists must refrain from lobbying their old agencies. Not a gift ban passed by the Congress to loosen the knot of friendship between lobbyists and lawmakers. Not even a major fund-raising scandal in which some of the city's premier lobbyists, including Haley Barbour, a former Republican Party chairman, and Peter S. Knight, a Democratic fund-raiser, were brought before Congressional oversight committees.
  • Some of the most expensive lobbying campaigns have sought to insure that nothing happens, like the $100 million effort to kill anti-tobacco legislation.
  • ''A lot of the best lobbyists are like paid assassins,'' said Jennifer Shecter of the Center for Responsive Politics, a research group in Washington.
  • Lobbyists have always been part of the capital's political fabric, but have never before been so intimately interwoven into the government. Twenty years ago, for example, most Washington law firms did little or no lobbying. Now virtually all of them have bustling lobbying practices, and some have even hired non-lawyers to increase their political clout.
  • In his fight against impeachment, President Clinton has reached out to a network of Democratic lobbyists, lawyers and political consultants, including Thomas Hale Boggs Jr., Jody Powell, Joseph P. O'Neill and Anthony T. Podesta, who participate in a daily conference call with White House officials to plot strategy. This daily bull session is organized by Steve Ricchetti, who recently returned to the White House after leaving to become a lobbyist.
  • Both Vice President Al Gore and Speaker Newt Gingrich have tight coteries of lobbyists who regularly advise them on political matters.
  • Political analyst Kevin P. Phillips, author of ''Arrogant Capital,'' worries that Washington has become what the Founding Fathers feared, a ''capital so privileged and incestuous in its dealings, that average citizens believe it is no longer accessible to the general public.''
  • Mr. Phillips added that there was nothing like Washington's ''massive, permanent lobbying elite'' in other foreign capitals.
  • Foreign countries, in fact, feel it is necessary to hire Washington lobbyists to have their voices heard. Tiny Azerbaijan is currently interviewing firms, even though the small republic has an embassy in Washington and limited resources. The reason? Its neighbors have Washington lobbyists.
  • At least 128 former members of Congress are now working as lobbyists. Although some found solace on K Street after they were defeated for re-election, others left office because they were offered giant salary increases to become lobbyists.
  • In 1993 and 1994, Ohio Republican Willis D. Gradison Jr. and Oklahoma Democrat Glenn English stepped down from their House seats in the middle of their terms for lucrative lobbying jobs.
  • Only 3 percent of the lawmakers who retired in the 1970's are currently on K Street; in the 1990's, at least 22 percent of those leaving have become lobbyists.
  • Even Robert Strauss, at 80 years old perhaps the most seasoned member of a generation of Democratic superlawyers, is amazed at how fast the revolving door spins. A former Democratic Party chairman and United States trade representative, Mr. Strauss said in a recent interview that lawyers now often went to work for the Government for a few years, not because they wanted a career in public service, but because ''they know that enables them to move on out in a few years and become associated with a lobbying or law firm and their services are in tremendous demand.''
  • To be sure, the long hours and lean salaries of Congressional aides have always led to turnover, but not this much, according to the Congressional Management Foundation. In 1987, for example, most administrative assistants in the House, the highest-ranking aides, had spent 5.5 years working in the Congress. In 1996, the average tenure had dropped to 4 years, a study first reported by National Journal said.
  • The length of tenure of senior Senate staffers has also dropped.
  • In a recent foundation survey, 58 percent of departing Congressional staffers cited a desire to earn more money as their reason for leaving; it was the second most frequent response given after a desire to pursue a different type of work.

The Million-Dollar Man -  A Tax Analyst Joins the Fold

  • PricewaterhouseCoopers, the accounting firm that hired Mr. Kies to lobby on tax issues for its clients, may have already recouped its investment.
  • Last spring and summer, Mr. Kies led a lobbying blitz for some of the biggest names in corporate America, including the General Electric Company, to maintain a lucrative tax break. The provision, which Mr. Kies's old committee estimated would cost $1.8 billion in Federal revenue over 10 years, allowed United States corporations to reduce taxes on their overseas operations. Mr. Kies headed a team of 10 other PricewaterhouseCoopers analysts and lobbyists in a successful effort to maintain the status quo.
  • When the Treasury Department announced its intention to kill the provision, Mr. Kies swung into action, meeting many times with with top Treasury officials, including Lawrence H. Summers, the Deputy Treasury Secretary. ''We spent hours and hours with Donald C. Lubick, the Assistant Secretary for Tax Policy,'' Mr. Kies said in a recent interview. Mr. Kies dealt with both men at the Joint Tax Committee, which evaluates the tax implications of legislation.
  • Mr. Kies pushed hard with a central argument: that the provision was not really a loophole and would not result in a revenue loss from multinational companies shifting more of their operations overseas. Using Rube Goldberg-like diagrams that Mr. Kies likes to draw to illustrate complex tax issues, he carried the day. In June, the Treasury Department decided not to make the change, at least for the time being.
  • It also helped Mr. Kies that his old boss, the House Ways and Means Chairman Bill Archer, and other influential Republican tax writers, weighed in on his side. Federal lobbying laws prohibit Mr. Kies from lobbying Mr. Archer or his old committee for one year after his departure, but they are not much of an impediment. Former officials circumvent the law simply by designing the lobbying strategy and then letting their clients or colleagues do the direct lobbying until their one-year cooling-off period is over.
  • Coming from the Joint Tax Committee, Mr. Kies had free rein to lobby at Treasury, but on his team, which included lobbyists from other firms, was a former Treasury Department official.
  • In an interview, Mr. Kies said that the old-fashioned stereotype of a back-slapping lobbyist trading on friendships was outmoded. Much of his time is spent crunching numbers and persuading Treasury officials and lawmakers that his analysis is on target. Of course, his political connections count, too, but Mr. Kies said of his old bosses, Mr. Archer and William V. Roth Jr., the Senate Finance Chairman, ''Archer and Roth generally do what they believe is right.''
  • ''They don't do things because someone who's a buddy of theirs comes to see them,'' he said.
  • Ari Fleischer, an aide to Mr. Archer, had high praise for Mr. Kies.
  • ''There are scores of top-notch lobbyists who have relationships but who don't have the great knowledge to go beyond a handshake,'' Mr. Fleischer said. ''Ken Kies is an exception. He's a well-respected expert on tax law and he came to be one of the Hill's most admired strategists.''
  • As the top aide at the Joint Tax Committee, Mr. Kies supervised a staff of more than 60. Almost every line of the sweeping tax bill passed last year was written by Mr. Kies. A year earlier, he helped break a three-year stalemate on how to make health coverage portable. Fortune Magazine named him ''Mr. Tax'' in a story on Washington's most powerful bureaucrats.
  • Without confirming or denying his salary, Mr. Kies stressed that he would have been making the same amount if he had stayed in the private sector instead of spending several years on a government salary. At Baker & Hostetler, the Cleveland-based law firm where he practiced tax law before 1994, he earned $500,000.
  • ''The whole world was bidding for him and he's worth far more than the great salary he is making,'' said former Congressman and Ways and Means Committee member Guy Vander Jagt, a Republican who worked with Mr. Kies when he was a Congressional staffer earlier in his career and who later practiced law with him at Baker & Hostetler. Mr. Vander Jagt tried to woo Mr. Kies back to the firm, but failed because it could not compete with PricewaterhouseCoopers's seven-figure offer.

Show Us the Money -  Fat Paychecks For Everyone

  • It has been nearly 15 years since Michael K. Deaver, a former Reagan White House aide turned lobbyist, sparked controversy when a Time Magazine cover story showed him flaunting his multimillion-dollar accounts and pictured him riding in a limousine. But earlier this year, Washingtonian Magazine, a glossy magazine that caters to the city's professional elite, had no trouble rounding up many of the city's 50 top lobbyists to pose for a group photo accompanying an article titled, ''Show Me the Money!'' Though he was not in the picture, Mr. Deaver is still a successful lobbyist at one of the city's premier public relations firms.
  • The nexus of lobbying and campaign fund-raising, which lawmakers and lobbyists used to make efforts to conceal, has also never been more graphically displayed. It is no coincidence that some of Washington's most successful lobbyists, such as Mr. Barbour and Daniel A. Dutko, a close adviser to Vice President Al Gore, are also leading fund-raisers for their respective parties.
  • Half of all political action committee contributions to Federal candidates and parties flow from Washington, with many donors listing K Street corridor zip codes. Two dozen lobbyists interviewed said they received hundreds of fund-raising solicitations from Congressmen and their parties last year, some shortly after a lobbying meeting with a particular lawmaker.
  • ''You can almost count on getting some kind of fund-raising solicitation after you've been to the Hill,'' said one lobbyist who insisted he not be named. ''The time in between has gotten shorter and shorter and it's gotten more and more brazen.''
  • When Mr. Andrews, the business lobbyist, recently signed up a trade association of home equity lenders as a client, one of the first pieces of advice he gave the association was to establish a political action committee. ''Under the current system, campaign giving and fund-raising are essential,'' he said. ''When it isn't done, it's noticed.''
  • Corporate interests that finance the largest portion of Washington's lobbying are fortifying their influence with record campaign contributions to Federal lawmakers. Even as the House moved to ban the large contributions to political parties that are known as soft money, the national parties scooped up $115 million in these big donations from business and other interests over the last 18 months. That is more than double the amount raised during a comparable period in the last non-Presidential election cycle. Microsoft Corporation, which opened a Washington government affairs office only three years ago but now has one of the largest fleets of lobbyists -- more than a dozen people and firms -- recently signed on through one of its executives as a member of the Republican Party's Team 100, its elite corps of $100,000 donors.
  • Labor unions, which are among the Democratic Party's biggest donors, also field large teams of lobbyists. Labor money and lobbyists played an important role late last year when the House defeated President Clinton's efforts to expand his trade authority.
  • In the past two years, serious scandals have erupted involving lobbyists and fund-raising, but few lobbyists have suffered serious consequences. James H. Lake, a prominent Republican lobbyist, was convicted of making illegal corporate campaign contributions as part of the Federal criminal investigation of Mike Espy, the former Agriculture Secretary. After Mr. Lake left the firm where he worked when the illicit contributions were made, he was offered a position as managing director of the Washington office of Burson-Marsteller, a public relations firm. Last January, Mr. Lake was fined $150,000, placed on probation and ordered to write a paper on Federal election laws. Mr. Lake's monograph was distributed to the 2,000 members of the American League of Lobbyists.
  • In April, Ms. Eppard, the transportation lobbyist, was indicted by a Federal grand jury in Boston on charges of accepting improper payments from a lobbyist and a businessman while she was on the House Transportation Committee chairman's staff. She has denied wrongdoing and is still lobbying, having won provisions for her clients in the sweeping highway bill passed this summer.

A Bipartisan Bazaar -  Peddling on Both Sides of the Fence

  • ''When I came to Washington, there was a small coterie of committee chairmen with iron-clad seniority and tremendous power,'' recalled Charls E. Walker, a former Treasury Department official during the Eisenhower administration who opened the capital's first non-lawyer lobbying shop in 1973, called Charls Walker Associates. ''On a tax issue, if you had the agreement of the chairman of Ways and Means, you could go out and play golf'' for the rest of the day.
  • These days, Mr. Walker said, ''you can't rest easy unless you've worked all the members.''
  • With new committee and subcommittee chairmen, and such a slender Republican majority, there are many more bases for lobbyists to cover. The demand for Democrats with ties to the Clinton-Gore administration and Republicans with connections to G.O.P. lawmakers has produced a veritable bazaar of political influence, with single companies and trade associations assembling all-star bipartisan lobbying teams. On the bankruptcy bill, for example, the American Financial Services Association showcased in its newsletter its ''team of highly experienced lobbyists and consultants,'' including two Republican firms, Barbour Griffith & Rogers and Timmons & Co., as well as Democratic bench strength from Verner, Liipfert, Bernard, McPherson and Hand, the law firm of former Treasury Secretary Lloyd Bentsen, and President Clinton's polling firm, Penn & Schoen Associates.
  • There have been many mergers of Democrats and Republicans in lobbying firms. In recent weeks there has been speculation that two respected House members, California Democrat Vic Fazio and New York Republican Bill Paxon, who are both retiring from the House this year, will join forces and open a new lobbying firm.
  • Parry, Romani & DeConcini, a firm that specializes in health and pharmaceutical lobbying, was long known for its connections to Orrin G. Hatch, the Republican Senate Judiciary Committee Chairman, and Dennis DeConcini, a former Democratic Senator from Arizona who joined the firm when he left the Senate in 1995.
  • Jack Valenti, president of the Motion Picture Association of America and a political veteran who was a top aide to President Lyndon Johnson, has been Hollywood's man in Washington for the last 32 years. He said he was nostalgic for the days when he employed a single lobbying firm, Akin, Gump, which is now one of seven firms that the film association keeps on retainer.
  • Mr. Valenti is himself a celebrated Washington insider who earns more than $1 million. Although he enjoys easy access to most lawmakers, he said he needed so many other lobbyists because the film association had an ever-broadening agenda of foreign and domestic issues before a host of committees and agencies, from the House Judiciary Committee to the Office of the United States Trade Representative.
  • ''I don't need any lobbyists for access or entree,'' Mr. Valenti said. ''I need troops in the field.''
  • Akin, Gump is still on Mr. Valenti's payroll, according to Congressional lobbying files. Another mainly Democratic firm, Verner, Liipfert, lobbies on Hollywood's trade and telecommunications issues. Still another Democrat in Mr. Valenti's lobbying arsenal is Mr. Podesta, whose brother, John, was once his lobbying partner and is now the President's top damage-control adviser on the Lewinsky imbroglio. Anthony Podesta lobbies on ratings issues for the television subsidiaries of the movie studios, according to the records. The film association has also hired Mr. DeConcini's firm and the firm of former Democratic Representative Marty Russo.
  • Mr. Valenti has also beefed up his Republican lobbying retinue, hiring Republicans like Mr. Vander Jagt, who said his services were in much greater demand after the Republicans won control of the House in 1994.

Field Draws Many -  The Experienced And the New Too

  • In an interview, Mr. Vander Jagt joked that his first years as a lobbyist after he retired in 1992 were so slow that, ''I would have represented Al Capone or Fidel Castro.'' That all changed after the election in November 1994.
  • Mr. Vander Jagt can offer the motion picture industry and other clients a feel for what the Republican leadership is thinking because he continues to reap the perks of being a former Congressman, attending weekly meetings of several groups that are open only to current and former Republican lawmakers. ''It's a lobbyist's dream to be sitting there with the committee chairmen and to find out what's going on,'' said Mr. Vander Jagt, who lobbies on tax and other issues. ''You have all the benefits of your former life and none of the hardships,'' he adds.
  • Children, wives and even siblings of lawmakers have hung out lobbying shingles. There is Linda Hall Daschle, the wife of the Democratic Senate leader, and a former top official at Federal Aviation Administration, who lobbies on aviation issues. Randy DeLay, the brother of House Whip Tom Delay, also has transportation clients. (An ethics complaint against Representative DeLay that was sparked by his brother's lobbying activities was dismissed last year by the House Ethics Committee).
  • The son of former Louisiana Senator J. Bennett Johnston is one of the city's most successful lobbyists. Mr. Johnston, former chairman of the Senate energy committee, joined his son in the business after he retired in 1996, and so did one of the former Senator's top aides. Their client roster brims with energy interests and they also lobby for clients on trade issues involving China.
  • Former Senator Bob Packwood, a former chairman of the Senate Finance Committee, left office after the Ethics Committee decided he should be expelled because sexual misconduct and allegations that he had given legislative favors to a lobbyist. During the first half of this year, Mr. Packwood's firm, Sunrise Research Corporation, took in $440,000 lobbying on tax and trade issues for blue-chip clients such as Northwest Airlines and Marriott International.
  • But even the young and inexperienced are entering the field of lobbying. Lobbying has become an academic field, with American University offering a popular course on it.
  • Andrew Lacy, 23, for example, is an alumnus of a two-week intensive lobbying program at American. From his perch on K Street at Marlowe & Company, he enthusiastically sets up client meetings on Capitol Hill and attends fund-raisers for lawmakers.
  • ''It's fun to meet a Senator or a Congressman and make your pitch,'' said Mr. Lacy, who is earning $25,000 as a beginner.
  • Mr. Lacy, who grew up on Maryland's Eastern Shore in a rural farm area where his father is in the agriculture business and his mother is a public school teacher, said he hopes to keep his lobbying job while he takes evening law classes.
  • James Thurber, a professor who runs a lobbying institute at American, gets well-known lobbyists like Mr. Boggs to teach the trade to fledgling lobbyists like Mr. Lacy. Professor Thurber's students are required to develop a lobbying plan and to make their pitch to a panel of mock lawmakers. ''We want them to feel the pressure of what it's like to be on a lobbying campaign,'' Professor Thurber said.
  • Mr. Lacy was persuasive in his lobbying assignment to discourage the mock lawmakers from restricting a computer practice known as ''spamming,'' where businesses send unsolicited E-mail to consumers. He got an A and a job offer from one of the graders, lobbyist Howard Marlowe.
  • Mr. Marlowe's clients include property owners and localities trying to win financing for beach conservation, a cause that Mr. Lacy said he is comfortable embracing. He said some of his friends were working for tobacco companies, something he said he understood but would not do. ''They are making ends meet,'' Mr. Lacy said. ''They are learning the system. They are getting a foot in the door of the business.''

The Right Connections -  Gore or Gingrich: Gucci Gulch Ties

  • As one of Mr. Gingrich's best friends in the House, the Minnesota Republican was in immediate demand. ''People were looking for G.O.P. consultants and lobbyists all over the place,'' Mr. Weber said in an interview. Mr. Weber now heads an eight-man office that reported lobbying revenues of $2.2 million in 1997.
  • Like Mr. Downey, Mr. Weber is still an inside player, jetting off earlier this year to join Mr. Gingrich at a Republican event in Palm Springs, Calif. And he, too, finds his new profession more rewarding in many ways. ''With no disrespect to Congress,'' Mr. Weber said, ''not everything you do as a Congressman is very exciting.''
  • Mr. Weber and Mr. Downey also have the luxury of turning down clients. Both men refused to work for the tobacco industry and Mr. Weber said he would not be comfortable registering as an agent for a foreign client.
  • Another former Republican lawmaker in demand is Bob Dole, the Republican Presidential candidate in 1996. He is now ''of counsel'' at the Washington-based law firm of Verner, Liipfert, where he said he does not lobby but provides strategic advice to clients.
  • But his former political prominence still lands him national platforms, such as an appearance on David Letterman's talk show earlier this summer. There, between jokes, he took a moment to criticize President Clinton for his stance toward Taiwan. He did not disclose that his firm represents Taiwan, a relationship that required him to register as a foreign agent. Asked if he should have, Mr. Dole said that he had been a supporter of Taiwan for years before he joined Verner, Liipfert.
  • Mr. Dole's firm, loaded with political superstars such as George J. Mitchell, the former Senate majority leader, and Ann W. Richards, the former Texas Governor, earned $19 million in lobbying fees last year, the most reported by any firm. Its partners also have contributed generously to Federal candidates and the political parties.
  • Senator John McCain, whose anti-tobacco and campaign finance overhaul bills were defeated amid a hailstorm of lobbying, said Washington would be dominated by moneyed interests as long as lobbyists remained at the hub of campaign fund-raising.
  • ''The lobbyists give out the soft money,'' said the Arizona Republican, whose campaign finance bill would ban soft money contributions. ''If you take away the soft money, you do really reduce the influence of these people.''
  • Consumer activist Ralph Nader, who has watched the growth of corporate influence in the capital for the last 30 years, agreed, but said Senator McCain did not go far enough. Mr. Nader advocates public funding of Federal elections as well as new mechanisms for building genuine citizens' lobbies.
  • ''Trying to reform lobbying is like trying to stop a leak,'' he said. ''You block the water here, and it just goes around the corner.''

2001 (Aug 28) - Passing of father, Sgt. Michael Farris Simon ( 1910 - 2001 ) 

Full newspaper page : [HN02DD][GDrive] / Clip above : [HN02DE][GDrive]

MAY 8, 2008

Cancer Research and Patient Care

Cancer survivors and health care industry representatives testified about cancer research and patient care. Topics included research funding and innovation, the quality of patient care, preventative medicine, early detection, and access to care for uninsured and minority groups. They also spoke about quality of life and survivors' concerns. close 

https://www.c-span.org/video/?205238-1/cancer-research-patient-care

2012 - VP of policy at Pfizer

https://www.youtube.com/watch?v=ej7jPaRNqGI 

Video channel "Genetic alliance"  ...   He says "patient engagement" is the big change, not genetics 

2016 (March 18) - NYTimes : "Biden Names Leader for ‘Moonshot’ Cancer Campaign"

Saved as PDF : [HN02DI][GDrive]  

Image of article : [HN02DJ][GDrive

WASHINGTON — Vice President Joseph R. Biden Jr. will announce on Friday a corporate executive to lead his “moonshot” cancer initiative, selecting an expert who began work in 2003 to lower barriers between science and cures.

Greg Simon, 64, who will be named executive director, took a job he may get to keep for only the last 10 months of the Obama administration. Mr. Simon, who is battling cancer himself, said he understood the urgency of the task.

“There are so many things in the cure process that take too long,” he said.

In June 2014, Mr. Simon received a diagnosis of chronic lymphocytic leukemia, a blood and bone marrow disease, and six months ago completed his first round of chemotherapy. He is now healthy, but while fighting the illness one of his close friends died, leaving two young children.

“The vice president has a chance to change the culture of science,” Mr. Simon said. “And if we can create new approaches that are a step away from the road scientists have long been traveling, in a year or two it will be a different road.”

Mr. Simon was an aide to Vice President Al Gore from 1991 to 1997, eventually leaving as his top domestic policy adviser to set up a lobbying and advisory firm. In 2003, he was lured by Michael R. Milken to start FasterCures, a charity intended to speed the translation between basic research and lifesaving medicines. In 2009, Mr. Simon left FasterCures to become senior vice president for patient engagement at Pfizer. He left Pfizer in 2012, and has been working since then as the chief executive of Poliwogg, a financial services company focused on investing in life sciences.

“With his amazing breadth of experience, both in the public and private sector, he will bring an invaluable knowledge of the health care landscape to the task force,” Mr. Biden said in a statement.

At FasterCures, Mr. Simon was a prominent voice for the potentially transformative effects of sequencing the human genome.

“In the lifetime of my generation, most of the diseases we are dealing with, if not cured, should be turned into treatable chronic diseases,” Mr. Simon said in 2007, speaking of a notion that was widely held at the time but that most researchers now believe was wildly optimistic. But even then, Mr. Simon said that to achieve such breakthroughs, “we have to have a new system.”

Mr. Simon has been critical of the Food and Drug Administration and the National Institutes of Health, organizations where, he once said, “curing disease is a byproduct of the system and not a goal.” He will now have to work closely with both agencies, which have representatives on the task force. Mr. Biden, whose son Beau died from cancer last year, is the chairman of the initiative, which hopes to promote a decade’s worth of advances in cancer research in five years. But with just $195 million in new funding, the task force is considered an exceedingly modest effort.

Mary Wooley, the president of ResearchAmerica, an advocacy group, said Mr. Simon had an unusual ability to bring together diverse groups of people to focus on a problem.

“Maybe with persistence, we can overcome the legacy systems and thinking that slow things down,” Ms. Wooley said.

2016 (May 22) - NYTimes - Wedding of child : "Elizabeth Walsh and Reid Simon: Just Friends With Places to Go"

Saved article (as PDF)  : [HN02DK][GDrive]  

Image of saved article : [HN02DL][GDrive

Elizabeth Marie Walsh, a daughter of Dr. Marie B. Walsh and Michael S. Walsh of Baton Rouge, La., was married May 21 to Michael Reid Simon, the son of Margo L. Reid and Gregory C. Simon of Bethesda, Md. The Rev. Andrew D. Sutton, a friend of the couple and a minister of the First United Methodist Church of Lafayette, La., officiated at the Carnegie Institution for Science in Washington.

Ms. Walsh, 26, is keeping her name. She is the associate director of product management at Evolent Health, a health care technology and services company in Arlington, Va.

Her father is a partner in Taylor, Porter, Brooks & Phillips, a law firm in Baton Rouge. Her mother is the director of the Louisiana Local Technical Assistance Program at the Louisiana Transportation Research Center on the campus of Louisiana State University. The program finances highway safety improvements in Louisiana.

Mr. Simon, who is also 26 and is known as Reid, works in Reston, Va., as a software development consultant with Microsoft.

His mother is a Bethesda-based consultant to arts and environmental organizations, including, most recently, the Glen Echo Park Partnership for Arts and Culture, the former amusement park in Glen Echo, Md., that is now an arts center. His father, who works in Washington, is the executive director of the White House Cancer Moonshot Task Force led by Vice President Joseph R. Biden Jr.

Ms. Walsh and Mr. Simon met in September 2008 during a pre-semester convocation at the University of Pennsylvania, from which they later graduated, she with two bachelor’s degrees, in international relations and political science, and he with a bachelor’s degree in systems science and engineering.

“In the brief time that we spoke, I found her to be smart, sassy and very confident,” Mr. Simon said.

They soon realized that they lived a floor apart in the same dormitory. “It wasn’t really where the cool kids were,” Mr. Simon said. They became fast friends.

“He was very kind and very smart, creative and inclusive,” Ms. Walsh said. “He had all the qualities you would want in a friend, especially when you’re trying to make other friends.”

In July 2009, he flew to visit her at her family’s home in Baton Rouge, where he stayed for three days, leading their families to “start becoming skeptical about our so-called friendship,” as Mr. Simon put it.

“I distinctly remember my mom being suspicious,” she said. “Moms just know.”

When she returned the favor by visiting his family for Thanksgiving, “nobody believed that we were just friends anymore,” Mr. Simon said.

By December, they were dating steadily, and were still dating in January 2011, when Ms. Walsh, now in her junior year, went on a five-month study-abroad program to Cape Town. In March, Mr. Simon boarded a plane for Cape Town.

“Getting together in South Africa was a sign of our deep commitment,” he said. “We were both very ambitious and very driven people who, by that time, felt very comfortable around each other.”

After graduation, both landed jobs in Washington, and last October, he proposed on a frigid, blustery day at Shenandoah National Park in Virginia, where they went hiking. As they began their descent in the face of fierce, cold winds, Mr. Simon suddenly dropped to one knee and pulled out an engagement ring.

“He was so nervous about dropping the ring that he was not willing to let it out of his hands,” she said, laughing. “I had to kind of fight him for it, and I finally managed to take it away and slip it on my finger.”

2019 (Nov 11)

General Session: Greg Simon, Biden Cancer Initiative; Acting President, MediMergent

Channel HLTH 

HLTH is the leading platform bringing together the entire health ecosystem, focused on health innovation and transformation. 

260 views  Nov 11, 2019

Can You Hear Me Now?: Engaging Patients in Accelerating the Development of New Cancer Therapies: Wednesday, October 30, 2019

https://www.youtube.com/watch?v=yyKtGCPBmAg

Our Company

We are a newly organized blank check company incorporated in Delaware, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions with respect to a potential initial business combination with us. While we may pursue an initial business combination with a company in any sector, we intend to focus our search on life science companies that are using artificial intelligence (“AI”), machine learning (“ML”) and big data to create and power a new model of drug discovery through research and development that is far faster, less expensive and more predictable than the decades-old system of drug development we still follow today.

With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, we believe the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes. We combine a unique team of thought leaders who have deep experience and national reputations within academia, government and industry that will enable us to attract and evaluate the over 250 companies utilizing these new tools across the life sciences industry.

The Human Genome Project Meets Moore’s Law

In 1996, it took all night to download a 1 MB image over a traditional phone line. Today, internet speeds are basically instantaneous, computing power is growing according to Moore’s Law and data storage is practically unlimited.

In 1996, it took 10 to 12 years and hundreds of millions of dollars to bring a drug to market. Today, it still takes 10 to 12 years, but now over $2.5 billion to develop a successful drug. This cost consists of approximately $1.4 billion out-of-pocket expenses and $1.2 billion of time costs.

We believe the need for a new system of drug discovery is obvious. According to the NIH, there are about 8,000 diseases but only 500 of which have FDA approved treatments. The vast majority of these treatments manage but do not cure, such as insulin for diabetes and statins for cholesterol. We cannot afford the time or money to develop therapies for all of these diseases at 10 to 12 years and billions of dollars each.

To address these unmet needs with cures and lower their associated costs requires a new approach to drug discovery. The advent of true AI and ML, combined with big data from millions of medical records and millions of compounds, provides the opportunity to re-engineer the drug discovery process to dramatically reduce the time between discovery and clinical trials, to develop new biomarkers and diagnostic tools, to design drugs that are more likely to work without being toxic, to more accurately predict the results of clinical trials and to provide better outcomes for millions of people. That is why many research organizations are predicting that all drugs will be developed using AI by 2030.

This is possible because Moore’s Law is finally meeting the Human Genome, the mapping of which was completed in 2002. We now have the ability to harness genetics, proteomics (the study of proteins) and big data to create the biopharma research and discovery engine for the 21st Century.

Market Opportunity

Healthcare costs in the United States have been rising faster than inflation for more than a decade. Total healthcare expenditures exceeded $4 trillion in 2020, representing nearly 19% of gross domestic product. At the same time, “baby boomers” have begun to enter the years of their life with the highest medical costs. Baby boomers are now 57 to 75 years of age and number approximately 75 million. The average senior citizen will spend nearly $400,000 on healthcare costs during their remaining lifetimes.

Pharmaceutical expenditures represent approximately 10% of the nearly $4 trillion healthcare expense as currently estimated. A substantial portion of those funds are spent to treat chronic conditions (such as

hypertension, high cholesterol and diabetes) and congenital lifelong conditions (including chronic kidney disease and sickle cell anemia). A large portion of the remainder is spent on the treatment of various forms of cancer.

A significant portion of the drugs developed over the past 30 years by large pharmaceutical companies are designed to treat the symptoms of chronic disease. More recently, the biotech industry has developed biologic treatments that interfere in the mechanisms of disease and in some cases can prevent disease altogether.

Of the 8,000 known diseases in the world, almost 7,000 are rare diseases (these are diseases with a patient population of less than 200,000, and while each disease is “rare,” collectively they impact millions of people). The majority of the more than 7,000 rare diseases were until very recently considered “undruggable,” either because they were based in the genetic code or because the mechanism of the disease was not understood. Since the Human Genome Project finished mapping the human genome in 2002, scientists have developed the capability to map and understand the genetic footprint of many diseases. They are no longer undruggable. Medical professionals have developed tools, such as CRISPR, which allow doctors to correct mistakes in the genome that cause disease. Suddenly, in just the past ten years, scientists have the ability to seek treatments that potentially lead to the cure of many diseases that have previously been undruggable. Curing a disease eliminates the substantial costs of chronic treatment.

While scientists now have the ability to create hundreds or even thousands of new drugs, the drug development process has not kept up with the advances in understanding biology. 2020 was a record year for novel drug approvals by the FDA, when 53 drugs were approved. An incredible amount of time and money goes into drug development. Bringing the average drug to market costs more than $2.5 billion and can take 10 to 12 years. This capital cost means the drugs must be expensive in order for the manufacturer to recoup its outlays, especially over a multi-year investment horizon. The singular focus on developing a few dozen drugs a year leaves many people untreated: estimates are that at least 150 million Americans have at least one chronic illness.

Utilizing AI and ML can accelerate the process dramatically while at the same time reducing costs and, more importantly, create drugs that are more effective with less side effects and toxicities. The venture capital community has recognized this potential. Healthcare AI startups were able to raise over $2 billion in the third quarter of 2020, with most of that money going to companies seeking to streamline the drug development process. Over the past five years, more than 250 startups have been funded in the AI/drug discovery space, raising almost $10 billion of venture capital.

AI and ML have already delivered substantial innovations in our society. Google Maps, digital assistants and e-payments have all become possible through AI and ML. Now, healthcare professionals are applying this science to drug discovery and development. Electronic health records have created massive data sets that can now be analyzed to accelerate the discovery of new targets for treatment. Along with scans of existing medical literature and genetic data sets, scientists can discover gene-disease associations identifying even more targets.

According to a study by researchers from the London School of Economics conducted on Food and Drug Administration (the “FDA”) approved data from 2009 to 2018, the average cost of bringing a drug to market was $1.3 billion (after accounting for the cost of failures). During this ten-year period, the FDA approved 355 drugs. When most diseases were thought to be undruggable, this rate of approval appeared sufficient. We believe that it no longer is. The development period for these drugs is at least 10 to 12 years and in some cases more than a decade. Both capital and time are gating issues in garnering drug approval. We believe that many millions of people will cost the healthcare system trillions of dollars suffering from diseases that could be mitigated or cured during their lifetimes. Instead of spending $1 billion per drug and taking several years, we need to (and likely can) reduce both the time and cost significantly through AI and ML.

As outlined above, the traditional drug development process is complex and lengthy. Developing a drug for any disease requires a lengthy preclinical and clinical development process. In short, the preclinical stage is an experimental stage of four to seven years including many steps in the current state-of-the-art process that requires a high level of educated guessing to reach an effective drug that can enter into clinical trials. These steps include:


identifying one of the molecules (genes/proteins) that are responsible for the disease through experimental discovery;

(2)

finding a drug that targets this molecule based on its three-dimensional structure, which requires a lengthy process of making the protein and developing its crystal structure;

(3)

experimentally screening arrays of millions of drugs and compounds that are publicly available, or synthesizing new drugs by predicting their structures on the basis of the protein’s three-dimensional structure, to identify the one that can target the molecule and correct or stop its function; and

(4)

refining the identified compounds to be suitable for human use by decreasing their potential toxicities and enhancing their functionality through modifying and synthesizing hundreds or even thousands of new forms of the compounds and experimentally conducting arrays of assays and animal experiments — a process that undergoes many cycles until a suitable one is identified.

The drug then moves to the clinical stage of an additional four to six years of three stages of clinical trials development: phase 1 to identify the spectrum of tolerability and dose that patients can be treated with; phase 2 to identify the efficacy of the drug in certain conditions; and phase 3 to establish the superiority of the new drugs over standard therapy. This lengthy, highly complex and extremely expensive process can be substantially shortened and made more efficient and less expensive through the utilization of AI, which can assist and sometimes replace some of the steps outlined above. This especially decreases the need for certain long and extensive experimentations and substantially increases the level of certainty during the process. Some of the AI contribution includes:

identifying proper molecular targets in specific diseases though molecular network mining and computer three dimensional modeling; and

identifying potential drugs through mining of millions of publicly available compounds using computer models of binding of the drug to the targeted molecule and further using specific algorithms and machine learning to improve these drugs and make them more suitable for human use.

This decreases, and in some cases eliminates, the need for lengthy experimental steps and can be much more accurate. On the clinical side, AI can help in identifying the appropriate patients to increase the potential of success in clinical trials.

Moderna Therapeutics is a biotech company that has received a large amount of press throughout 2020 surrounding its development of an mRNA vaccine candidate for COVID-19, mRNA-1273. Founded in 2010, a time when many companies were beginning to undergo digital transformation, of which AI/ML is a fundamental building block, Moderna looked to incorporate digitization as a “core attribute and key enabler” in its business model and infrastructure from inception. By embracing advanced analytics early on, alongside its focus on mRNA-based therapeutics, Moderna has been able to efficiently identify high potential drug candidates for further investment. Machine learning technology further speeds up the development process by optimizing the mRNA sequence for manufacturing and testing. The efficiency this process offers is clearly seen in the development of mRNA-1273, which was ready to initiate phase 1 clinical trials in a record-breaking 42 days and which went through all clinical testing and approval in record time. Given the complexity and cost associated with the traditional drug discovery process, if successful, this approach has the potential to revolutionize drug development and, in turn, the biopharma industry.

We believe that current market dynamics support our differentiated ability to identify and nurture private companies that embody the potential of AI/drug discovery. We believe that we will be an attractive financing alternative for AI companies given the depth and breadth of our team’s experience. Partnering with our company can be an efficient means to unlocking innovation value through the public markets.

Acquisition Strategy

We believe our management team is well-positioned to identify unique opportunities in the healthcare sector, particularly in areas in which AI, quantum computing and biomedicine converge. Our selection process will leverage our extensive network of relationships with senior executives in both private and public

companies, unique access to deal flow from top-tier venture capital and private equity funds and leading investment banking firms. We believe that our management team’s reputation, depth of operating and investing experience, history of structuring and executing mergers and acquisitions and other transactions, will make us a preferred partner for these potential targets.

Consistent with our strategy, we have identified the following criteria to evaluate prospective target businesses. We intend to seek to acquire companies that we believe are characterized by one or more of the themes below:

data-driven approaches to accelerate the drug discovery and development process;

the collection and analysis of real world evidence to inform expanded or novel uses of existing drugs; and

novel biologics in pursuit of solutions for diseases that have largely been considered undruggable to date.

Any company that we target, in addition to being characterized by one or more of the areas of focus described above, should be ready to be a publicly-traded company, with strong management and reporting policies in place. Lastly, we would expect the target to have unrecognized value or growth characteristics that we believe are likely to be appreciated by the market in the short term, thus enabling above-average risk-adjusted returns.

Our Officer

Our officer is Gregory C. Simon (Chief Executive Officer and Chief Financial Officer), who brings a combination of strategic, scientific, technological and operational experience paired with a track record of being at the forefront of technological and scientific advances. We believe our officer’s expertise will make us an attractive partner to potential target businesses, and will bring unique value creation opportunities through his networks.

Gregory C. Simon serves as our Chief Executive Officer, Chief Financial Officer and member of our board of directors. Most recently, Mr. Simon was the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. In 2017, Mr. Simon co-founded and served as President of the Biden Cancer Initiative. Previously In his career, Mr. Simon held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, and was a senior strategy consultant to a variety of international technology CEO’s. With Michael Milken, Mr. Simon co-founded and led FasterCures and the Melanoma Research Alliance. He was the Senior Vice President at Pfizer for worldwide policy and public engagement and was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Mr. Simon is currently a member of the board of directors of WinSanTor Inc., a biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.


2022 (Feb) - People who dont get vaccinated against COVID, are killing people with cancer ..

https://www.youtube.com/watch?v=trXP_nc7vEc 

DIRECTORY INFO

Ancestry.com directory info 

Saved as : [HD004E][GDrive

Whitepages.com - Gregory C. Simon (Bethesda, as of July 22 2023)

Saved as : [HD004D][GDrive

Relatives & Associates

Family  - Father is Michael Farris Simon 

https://www.findagrave.com/memorial/59628376/michael-farris-simon?_gl=1*ow0213*_gcl_au*MTY2MDMzOTk0LjE2ODUxMjYwMzI.*_ga*MzExNzA1NzgzLjE2Njc1Mjg2MzE.*_ga_4QT8FMEX30*MzhhYzkyZDctMmY4Ni00ZWM0LWE1ZTgtOTZlMzEzMWI0ZjA1LjEyMC4xLjE2OTA4NTc0NDkuMTguMC4w

Sgt Michael Farris Simon   (  Sgt, US army, WW2 )

Interesting person, that Whitepages.com suggests is related, but that is probably wrong - "Barry Steven Simon"

Barry S. Simon (brother) - Ancestry.com, from the U.S., Public Records Index, 1950-1993, Volume 1

Saved as PDF : [HD004F][GDrive

Whitepages (July 29, 2023) - "Barry Steven Simon"

Saved as PDF : [HD004G][GDrive

More...

Detail Source

Name

Mike Simon

Birth Date

15 Jan 1910

[15 Jan 1913]

Residence Date

1993

Phone Number

763-6117

Address

300 E Missouri St

Residence

Blytheville, AR

Postal Code

72315-2945

Second Residence Date

1993

Second Phone Number

763-6117

Second Address

300 E Missouri St

Second Residence

Blytheville, AR

Second Postal Code

72315-2945


https://www.ancestry.com/discoveryui-content/view/135997473:1788?tid=&pid=&queryId=49b7aa930935418de7bcb5cd652133e6&_phsrc=kyz746&_phstart=successSource



https://www.ancestry.com/discoveryui-content/view/15113683:2238?tid=&pid=&queryId=49b7aa930935418de7bcb5cd652133e6&_phsrc=kyz747&_phstart=successSource 

Name

Mike Farris Simon

Gender

Male

Age

28

Relationship to Draftee

Self (Head)

Birth Date

15 Jan 1912

Residence Place

Blytheville, Mississippi, Arkansas, USA

Registration Date

16 Oct 1940

Registration Place

Blytheville, Mississippi, Arkansas, USA